PD-1 Antibodies and PD-L1 Antibodies and Uses Thereof

• US 20120039906A1
• Filed: 02/09/2010
• Published: 02/16/2012
• Est. Priority Date: 02/09/2009
• Status: Active Grant

• Current Assignee: Institute Paoli-Calmettes, Université d'Aix-Marseille
• Original Assignee: Inser, Universite de la Mediterranee
• Inventors: Olive, Daniel
• Granted Patent: US 8,741,295 B2
• Time in Patent Office: Days
• US Class Current: 424/158.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07K 16/2827 against B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/74 Inducing cell proliferation
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof.

Claims

1. A PD-L1 antibody, which stabilizes the binding of PD-L1 to PD-1.

4. A method for treating the human or animal body by therapy, comprising administering a PD-L1 antibody according to any one of claims 1 to 3 to said human or animal body.

5. A method according to claim 4 for treating an autoimmune disease, transplantation rejection or a graft versus host disease.

2. A PD-L1 antibody obtainable from the hybridoma accessible under CNCM deposit number I-4080 or I-4081.

3. A PD-L1 antibody, which stabilizes the binding of PD-L1 to PD-1, comprising the CDRs of the PD-L1 antibody of claim 2.

6. A hybridoma cell line selected from the group consisting of CNCM I-4122, CNCM I-4080 and CNCM I-4081.

7. A PD-1 antibody obtainable from the hybridoma accessible under CNCM deposit number I-4122.

8. A PD-1 antibody comprising the CDRs of the PD-1 antibody of claim 7.

9. A method for treating the human or animal body by therapy, comprising administering a PD-1 antibody according to claim 7 to said human or animal body.

10. A method according to claim 9 for wherein said therapy is for a cancer or a chronic infection.

11. A vaccine for the treatment of a cancer or a chronic infection comprising a PD-1 antibody according to claim 7.

12. A kit for the treatment of a cancer or a chronic infection comprising:

a) a PD-1 antibody according to claim 7; and

b) a vaccine for the treatment of a cancer or a chronic infection.

13. A method for treating the human or animal body by therapy, comprising administering a PD-1 antibody according to claim 8 to said human or animal body.

14. A method according to claim 13 wherein said therapy is for cancer or a chronic infection.

15. A vaccine for the treatment of a cancer or a chronic infection comprising a PD-1 antibody according to claim 8.

16. A kit for the treatment of a cancer or a chronic infection comprising:

a) a PD-1 antibody according to claim 8; and

b) a vaccine for the treatment of a cancer or a chronic infection.